Financial Summary for the Fiscal Year Ending June 2026 (Japanese GAAP) (Consolidated)

Overview of Business Performance

This fiscal year, consolidated net sales were 3,871 million yen, operating income 275 million yen, and net income attributable to owners of the parent 212 million yen. By segment, contributions came from Biometric Evaluation Systems, Healthcare Support, Cosmetics, Health Supplements, and Functional Materials Development. Overall, net sales declined versus the previous year. The financial results summary notes a restructuring as part of a portfolio overhaul, including retreat from the Chinese market and organizational integration. For the next year, the company will focus on the Healthcare Platform business and strengthen domestic and international expansion.

Outlook and Dividend Policy

For the next fiscal year (the year ending June 2027), consolidated projections are net sales of 3,270 million yen, operating income of 300 million yen, ordinary income of 310 million yen, and net income attributable to owners of the parent of 250 million yen. The company plans to build a comprehensive healthcare platform powered by medical DX, with expanded domestic and international deployment. In terms of shareholder returns, a year-end dividend of 10 yen per share is planned, with an annual dividend of 10 yen expected for the next year as well.